Mirikizumab as Induction and Maintenance Therapy in Chinese Patients with Ulcerative Colitis: A Subpopulation Analysis of the Randomized, Global Phase 3 LUCENT-1 and LUCENT-2 Trials. - Ran Z; Chen Y; Miao Y; Wang Y; Gao X; Zhong J; Ding X; Wang C; Zhang X; Ding Y; Hu N; Tang D; et al. (BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2026)